Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Seoul
Clinical trial register · South Korea

Clinical Trials in Seoul, 2026

Every study on the ClinicalTrials.gov registry that lists a site in South Korea and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3409 matching records held by the registry are in this view. Synced 17 Nov 2026, 03:18 UTC
3409
Studies in scope
all four open statuses
1874
Recruiting now
open to new participants
512
Lead sponsors
across recruiting studies
Top sites
Seoul 2866 Daegu 553 Seongnam-si 485 Busan 470 Goyang-si 399

Trials with a site in Seoul

2866 of 3409 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in South Korea
Start
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
270
Seoul
2025-03-25
Active, closed
Astria Therapeutics, Inc.
Phase 3
157
Seoul, Yangcheon, Seongnam-si
2025-03-20
Recruiting
AstraZeneca
Phase 3
990
Anyang-si, Daegu, Iksan-si, Jeonju, Seoul, Uijeongbu-si, Wŏnju
2025-03-18
Active, closed
Amgen
Phase 3
1,105
Ansan-si, Gyeonggi-do, Daegu, Seongnam-si, Gyeonggi-do, Seoul, Wonju-si, Gangwon-do
2025-03-17
Recruiting
Hoffmann-La Roche
Phase 3
600
Busan, Daegu, Daejeon, Gangwon-do, Guri-si, Seoul
2025-03-17
Active, closed
Hoffmann-La Roche
Phase 4
274
Busan, Daegu, Seongnam-si, Seoul
2025-03-14
Recruiting
AstraZeneca
Phase 3
11,300
Bucheon-si, Cheongju-si, Daegu, Seongnam-si, Seoul, Suwon, Wŏnju, Yangsan
2025-03-14
Active, closed
Celgene
Phase 3
960
Goyang-si, Seongnam, Seoul
2025-03-13
Recruiting
IVUS-Guided vs Angiography-Guided PCI in Acute Coronary Syndrome
NCT07512778Acute Coronary Syndromes (ACS)
SUK MIN SEO
Not applicable
1,500
Seoul
2025-03-13
Active, closed
AstraZeneca
Phase 2
82
Seoul, Yongin-si
2025-03-12
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Seoul
2025-03-12
Recruiting
Long-term Follow up Local Registry Study of Kymriah in South Korea
NCT06785818B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Novartis Pharmaceuticals
Observational
500
Bundang Gu, Seongnam-si, Gyeonggi-do, Incheon, Seoul, Busan, Jeollanam, Ulsan
2025-03-12
Recruiting
AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
NCT06911333Solid Tumor, Adult, Tumor, Solid, Solid Tumor, Solid Tumor, Unspecified, Adult
Avelos Therapeutics Inc.
Phase 1/2
36
Seongnam-si, Seoul
2025-03-11
Recruiting
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
NCT06687941Neoplasms, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms
Aptamer Sciences, Inc.
Phase 1
70
Goyang-si, Seongnam, Seoul
2025-03-11
Recruiting
Pfizer
Phase 3
723
Hwaseong-si, Gangseo-gu, Seoul
2025-03-11
Recruiting
Yonsei University
Not applicable
44
Seoul
2025-03-11
Recruiting
Seoul National University Hospital
Phase 2
100
Gangneung, Anyang-si, Ilsan, Seongnam-si, Seoul
2025-03-11
Recruiting
Addpharma Inc.
Phase 1
60
Seoul
2025-03-10
Recruiting
Yonsei University
Phase 2
52
Seoul
2025-03-10
Active, closed
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
NCT06744647Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
Alexion Pharmaceuticals, Inc.
Phase 2
47
Seoul
2025-03-07
Recruiting
BeOne Medicines
Phase 3
300
Seogu, GangnamGu, SeochoGu, Seoul, SongpaGu, Yeongdeungpo-gu
2025-03-05
Active, closed
An Ophthalmic Safety Study in Patients With Breast Cancer
NCT06767462Ophthalmic Safety in Patients With Breast Cancer
AstraZeneca
Observational
160
Seoul
2025-03-05
Recruiting
Hoffmann-La Roche
Phase 2
130
Seongnam-si, Seoul
2025-03-05
Recruiting
GlaxoSmithKline
Phase 1/2
305
Seoul
2025-03-04
Recruiting
AstraZeneca
Phase 3
5,000
Ansan-si, Anyang-si, Busan, Cheonan-si, Goyang-si, Gwangju, Seongnam-si, Seoul
2025-03-03
Active, closed
Takeda
Phase 3
1,583
Suwon, Seoul
2025-03-03
Not yet open
Effects of Short Foot Exercise on Knee Pain, Muscle Tone, Balance, and Quality of Life in Flexible Flatfoot Patients
NCT06861322Flexible Flatfoot, Knee Pain, Balance Impairment, Quality of Life (QOL)
Sahmyook University
Not applicable
44
Seoul
2025-03-02
Not yet open
Seoul National University Hospital
Not applicable
60
Seoul
2025-03-01
Not yet open
Ewha Womans University Seoul Hospital
Not applicable
400
Seoul
2025-03-01
Not yet open
Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry
NCT06843421Metabolic Dysfunction-Associated Steatotic Liver Disease, Cardiovascular Diseases
Korea University
Observational
6,000
Gyeonggi-do, Yongin, Seoul, Gangwon-do, Suwon
2025-03-01
Recruiting
AstraZeneca
Phase 3
840
Daegu, Goyang-si, Gyeonggi-do, Jeonnam, Seoul
2025-03-01
Not yet open
Yonsei University
Not applicable
5,200
Seoul
2025-03
Recruiting
Incyte Corporation
Phase 3
600
Ansan-si, Busan, Incheon, Seoul, Yangsan
2025-02-28
By invitation
Digital Phenotypes for Predicting Depression
NCT07151846Depression - Major Depressive Disorder, Depression Bipolar, Bipolar Disorder (BD), Mood Disorders
Korea University Anam Hospital
Observational
540
Seoul
2025-02-27
Recruiting
Takeda
Phase 3
171
Seongnam-si, Daegu, Seoul
2025-02-27
Recruiting
HK inno.N Corporation
Observational
5,217
Seoul
2025-02-27
Recruiting
Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
NCT06928818Cancer of Breast, Trastuzumab Emtansine, Trastuzumab Deruxtecan
Seoul National University Hospital
Observational
100
Seoul
2025-02-26
Active, closed
Amgen
Phase 2
252
Cheongju Chungbuk, Daegu, Hwasun-gun, Jeollanam-do, Seongnam-si, Gyeonggi-do, Seoul
2025-02-26
Recruiting
Seong Hye Choi, MD
Not applicable
40
Incheon, Seoul, Suwon
2025-02-26
Recruiting
Amgen
Phase 3
844
Seoul
2025-02-25
Recruiting
Yonsei University
Observational
360
Seoul
2025-02-25
Recruiting
Asan Medical Center
Not applicable
20
Seoul
2025-02-25
Recruiting
Korean Joint Registry for Alzheimer's Treatment and Diagnostics (JOY-ALZ)
NCT06889818Mild Cognitive Impairment, Dementia, Subjective Cognitive Decline (SCD), Alzheimer Disease
Ewha Womans University Mokdong Hospital
Observational
4,000
Incheon, Seoul
2025-02-24
Recruiting
Boryung Pharmaceutical Co., Ltd
Phase 1
20
Seoul
2025-02-24
Recruiting
Prevail Global Study
NCT06535854Coronary Artery Disease
Medtronic Vascular
Not applicable
1,205
Daegu, Seoul
2025-02-24
Recruiting
UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies
NCT06590961Relapsed/Refractory B-cell Malignancies
Ubix Therapeutics, Inc.
Phase 1
94
Seoul
2025-02-20
Recruiting
Hong Joonpio
Not applicable
114
Seoul
2025-02-20
Active, closed
Sanofi
Phase 3
231
Cheonan-Si, Seongnam-si, Incheon, Seoul
2025-02-12
Active, closed
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
NCT06770933Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Vantage Biosciences Ltd
Phase 2
100
Seongnam-si, Seoul
2025-02-11
Active, closed
Lipoprotein(a) and Progression of Aortic Stenosis
NCT06648915Aortic Valve Stenosis, Lipoprotein(a)
Asan Medical Center
Observational
364
Seoul
2025-02-10
Active, closed
AbbVie
Phase 3
468
Hwaseong, Seoul
2025-02-10
Recruiting
Dianthus Therapeutics
Phase 3
256
Daegu, Daejeon, Seoul, Uijeongbu-si, Yangsan
2025-02-10
Recruiting
Skin-to-skin Contact in Healthy Term Infants
NCT06777524Skin-to-skin Contact
Korea University Anam Hospital
Not applicable
130
Seoul
2025-02-10
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Busan, Seoul
2025-02-07
Recruiting
Seoul National University Hospital
Phase 4
140
Seongnam-si, Seoul
2025-02-06
Recruiting
Smartwatch-Based AI Model for OSA Prediction (SWOSA)
NCT06792188Obstructive Sleep Apnea of Adult, Screening, Smart Watch
Seoul National University Hospital
Observational
147
Seoul
2025-02-03
Recruiting
BioNTech SE
Phase 3
621
Seoul, Goyang-si, Suwon, Jinju, Incheon, Cheongju-si
2025-02-03
Recruiting
Gangnam Severance Hospital
Not applicable
134
Seoul
2025-02-01
Recruiting
Sir Mortimer B. Davis - Jewish General Hospital
Observational
4,700
Seoul
2025-02-01
Not yet open
Transanal Irrigation for Low Anterior Resection Syndrome
NCT06796296Low Anterior Resection Syndrome, Rectal Cancer Surgery, Insomnia
Seoul National University Hospital
Not applicable
94
Seoul
2025-02-01
Recruiting
Gangnam Severance Hospital
Not applicable
36
Seoul
2025-02-01
By invitation
Pharvaris Netherlands B.V.
Phase 3
170
Daegu, Seoul
2025-02-01
Recruiting
Severance Hospital
Phase 3
178
Seoul
2025-02-01
Not yet open
Yonsei University
Phase 3
40
Seoul
2025-02
By invitation
Novo Nordisk A/S
Observational
244
Seoul
2025-01-31
Recruiting
Gangnam Severance Hospital
Not applicable
48
Seoul
2025-01-30
Recruiting
Venetoclax and Decitabine in R/R T-ALL
NCT06712121T Lymphoblastic Leukemia/Lymphoma
Seoul National University Hospital
Phase 2
28
Seongnam-si, Seoul
2025-01-30
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
AstraZeneca
Phase 1/2
408
Busan, Seoul
2025-01-30
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Hwasun-gun, Busan, Daegu, Seongnam, Seoul
2025-01-29
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics
Phase 2/3
650
Busan, Goyang-si, Hwasun, Seongnam, Seoul
2025-01-28
Recruiting
SB17170 Phase 2 Trial in IPF Patients
NCT06747923IPF, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
SPARK Biopharma
Phase 2
30
Goyang, Gwangmyeong, Seoul, Suwon
2025-01-27
Recruiting
Seoul National University Hospital
Not applicable
50
Seoul
2025-01-27
Recruiting
Jeeyun Lee
Phase 2
100
Seoul
2025-01-22
Recruiting
Takeda
Phase 3
70
Daegu, Seoul
2025-01-22
Recruiting
Korea University Anam Hospital
Observational
80
Seongnam-si, Seoul
2025-01-20
Recruiting
Korea University Anam Hospital
Phase 4
30
Seoul
2025-01-20
Recruiting
Korea University Anam Hospital
Not applicable
15
Seoul
2025-01-17
Recruiting
Seoul National University Hospital
Phase 1/2
21
Seoul
2025-01-17
Recruiting
Seoul National University Hospital
Not applicable
104
Seoul
2025-01-15
Active, closed
argenx
Phase 3
631
Anyang-si, Suwon, Gwangju, Seoul
2025-01-15
Active, closed
Korea University
Not applicable
30
Seoul
2025-01-14
Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer
Jazz Pharmaceuticals
Phase 2
200
Suwon, Hwasun-Eup, Gangnam-gu, Guro-gu, Jongno-gu, Seodaemun-gu, Seoul
2025-01-14
Recruiting
A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor
NCT06365840TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors
ImmuneOncia Therapeutics Inc.
Phase 2
30
Goyang, Seongnam, Seoul
2025-01-13
Recruiting
Asan Medical Center
Not applicable
60
Seoul
2025-01-10
Recruiting
BeOne Medicines
Phase 1
695
PaldalGu SuwonSi, Seongnam-si, GangnamGu, SeodaemunGu, Seoul, SongpaGu
2025-01-10
Recruiting
Seoul National University Hospital
Not applicable
190
Seoul
2025-01-09
Recruiting
BlossomHill Therapeutics
Phase 1/2
675
Seoul
2025-01-09
Recruiting
IRIS-Coroflex NEO Cohort
NCT06177743Coronary Artery Stenosis, Coronary Artery Disease
Seung-Jung Park
Observational
1,000
Seoul, Bucheon-si, Daegu, Gwangju, Ilsan, Sejong, Suwon, Uijeongbu-si
2025-01-09
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Seogu, Gwangju, Anyang-si, Seongnam-si, Seoul
2025-01-08
By invitation
PharmaResearch Co.,Ltd
Phase 3
260
Seoul
2025-01-08
Recruiting
BioNTech SE
Phase 2/3
1,580
Cheongju-si, Daejeon, Goyang-si, Incheon, Jinju, Seongnam-si, Seoul, Suwon
2025-01-07
Active, closed
Pfizer
Phase 3
1,035
Seongnam-si, Incheon, Goyang-si, Seongnam, Gangnam-gu, Seoul
2025-01-06
Not yet open
HUINNO Co., Ltd
Not applicable
270
Busan, Seongnam, Seoul
2025-01-06
Recruiting
JW Pharmaceutical
Phase 1
72
Seoul
2025-01-06
Active, closed
Daiichi Sankyo
Phase 2
335
Goyang-si, Seoul
2025-01-06
Recruiting
Loxo Oncology, Inc.
Phase 2
249
Busan, Hwasun-gun, Seoul
2025-01-03
Recruiting
Takeda
Phase 3
396
Busan, Daegu, Daejeon, Seoul, Suwon
2025-01-02
Not yet open
Digital CBT-I for Chronic Insomnia
NCT06695000Insomnia Chronic, Insomnia Disorder
WELT corp
Not applicable
120
Goyang-si, Yongin-si, Seoul
2025-01
Recruiting
Samsung Medical Center
Phase 4
408
Seoul
2024-12-31
Active, closed
mAbxience Research S.L.
Phase 3
726
Busan, Gyeonggi-do, Incheon, Seoul
2024-12-30
Recruiting
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
NCT06600321Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
Alnylam Pharmaceuticals
Phase 1
158
Busan, Seongnam, Seoul
2024-12-30
By invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
NCT06788509Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
Janssen Research & Development, LLC
Phase 1
120
Seoul
2024-12-30
Recruiting
Robot-Assisted Neurovascular Intervention
NCT06752096Stroke, Meningioma, Neurovascular Disorder
Navigantis Inc.
Not applicable
10
Seoul
2024-12-27
Active, closed
Amgen
Phase 2
61
Seongnam-si, Gyeonggi-do, Seoul, Suwon-si Gyeonggi-do, Suwon-si, Gyeonggi-do
2024-12-26
Recruiting
Pharmicell Co., Ltd.
Observational
32
Seoul
2024-12-26
Recruiting
Seoul National University Hospital
Observational
30
Seoul
2024-12-24
Recruiting
Asan Medical Center
Observational
200
Seoul
2024-12-20
Active, closed
Janssen Research & Development, LLC
Phase 1
17
Seoul
2024-12-19
Recruiting
PAQ Therapeutics, Inc.
Phase 1
300
Seongnam, Seoul
2024-12-19
Recruiting
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
NCT06747585Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
Alentis Therapeutics AG
Phase 1/2
235
Goyang-si, Seoul
2024-12-16
Active, closed
Institut de Recherches Internationales Servier
Phase 1/2
55
Seongnam, Seoul
2024-12-16
Recruiting
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
NCT06312644Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS)
Alexion Pharmaceuticals, Inc.
Observational
75
Seoul
2024-12-16
Recruiting
S-Alpha Therapeutics, Inc.
Observational
40
Seoul, Hwaseong-si, Gwangmyeong, Incheon
2024-12-16
Not yet open
HK inno.N Corporation
Phase 1
80
Seoul
2024-12-16
Recruiting
Stress Urinary Incontinence for Female Patients (CGM MUIT-2301)
NCT07440927Stress Urinary Incontinence (SUI)
Ceragem Clinical Inc.
Not applicable
96
Seoul
2024-12-13
Active, closed
GlaxoSmithKline
Phase 1/2
14
Daegu, Gyeonggi-do, Seoul
2024-12-13
Active, closed
Arcus Biosciences, Inc.
Phase 3
610
Hwasun, Seongnam, Seoul
2024-12-13
Active, closed
HanAll BioPharma Co., Ltd.
Phase 4
50
Ansan, Jeonju, Kwangju, Seongnam, Seoul, Suwon
2024-12-12
Recruiting
Hyundai Pharm
Phase 2
160
Seoul
2024-12-12
Recruiting
Asan Medical Center
Not applicable
455
Seoul
2024-12-12
Recruiting
GlaxoSmithKline
Phase 3
514
Bucheon Kyunggi-Do, Seoul, Suwon Kyunggi-do, Yongsan-Ku Seoul
2024-12-12
Recruiting
Yonsei University
Phase 2
40
Daegu, Daejeon, Hwasun, Jeju City, Pusan, Seoul
2024-12-11
Recruiting
Hanmi Pharmaceutical Company Limited
Phase 1
292
Seongnam-si, Seoul
2024-12-11
Recruiting
Basilea Pharmaceutica
Phase 3
450
Daegu, Seoul, Suwon
2024-12-11
Recruiting
Daewoong Pharmaceutical Co. LTD.
Phase 1
84
Seoul
2024-12-10
Recruiting
PepGen Inc
Phase 2
24
Pusan, Daegu, Seoul
2024-12-10
Recruiting
Yonsei University
Observational
100
Seoul
2024-12-10
Recruiting
Pharosgen Co.,Ltd
Phase 1
24
Seoul
2024-12-10
Recruiting
Seoul National University Hospital
Phase 4
80
Seoul
2024-12-09
Active, closed
Vicore Pharma AB
Phase 2
378
Bucheon-si, Busan, Goyang-si, Seoul
2024-12-09
Active, closed
Amgen
Phase 3
707
Daejeon, Goyang-si, Gyeonggi-do, Seongnam-si, Gyeonggi-do, Seoul
2024-12-09
Recruiting
BeOne Medicines
Phase 1
168
BundangGu SeongnamSi, Seongnam-si, BukGu, NamdongGu, GangnamGu, SeodaemunGu, Seoul, SongpaGu
2024-12-09
Recruiting
Development and Utilization of an Integrated Clinical Genomic Database
NCT07911267Gastric Cancer, Colorectal Cancer, Lung Cancer (NSCLC), Liver Cancer
Samsung Medical Center
Observational
118,750
Seoul
2024-12-06
By invitation
Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
NCT07064525Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure, Diabete Mellitus
Shin Poong Pharmaceutical Co. Ltd.
Phase 2
252
Seoul
2024-12-05
Active, closed
Phase II Study of PG-102(MG12) Compared With Placebo in Obesity and Type 2 Diabetes
NCT06712615Type 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus
DrugPG-102
ProGen. Co., Ltd.
Phase 2
144
Bucheon-si, Daegu, Daejeon, Seongnam, Seoul
2024-12-05
Recruiting
Yuhan Corporation
Phase 3
60
Gyeonggi-do, Jeollanam-do, Jeollabuk-do, Seoul
2024-12-04
Active, closed
Janssen Research & Development, LLC
Phase 3
655
Gwangju, Seongnam-si, Seoul, Suwon
2024-12-04
Recruiting
Daewoong Pharmaceutical Co. LTD.
Observational
12,000
Seoul
2024-12-03
Recruiting
Yonsei University
Not applicable
330
Seoul
2024-12-03
Active, closed
H. Lundbeck A/S
Phase 3
401
Seoul
2024-12-03
By invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT06679946Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Alnylam Pharmaceuticals
Phase 3
700
Seoul
2024-12-03
Recruiting
JW Pharmaceutical
Phase 3
162
Seoul
2024-12-02
Recruiting
Novo Nordisk A/S
Phase 2
465
Goyang-si, Busan, Gyeonggi-do, Seoul
2024-12-02
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,082
Wŏnju, Gwangju, Ansan-si, Jinju, Pusan, Deagu, Seoul
2024-12-02
Recruiting
Yonsei University
Observational
80
Seoul
2024-12-01
By invitation
Seoul National University Hospital
Not applicable
500
Seoul
2024-12-01
Recruiting
Soonchunhyang University Hospital
Observational
200
Seoul
2024-12-01
By invitation
Comparing Immediate Removal and Postoperative 1 Day of Urinary Catheter After Colorectal Cancer Surgery
NCT06769087Colorectal Cancer, Postoperative Complication, Urinary Retention Postoperative, Enhanced Recovery After Surgery
Seoul St. Mary's Hospital
Not applicable
316
Seoul
2024-12-01
Active, closed
Head Position Monitoring After Pars Planar Vitrectomy
NCT06985030Retinal Detachment, Macular Hole
Seoul National University Hospital
Observational
100
Seoul
2024-11-28
Active, closed
Merck Sharp & Dohme LLC
Phase 2
120
Seoul
2024-11-27
Recruiting
AstraZeneca
Phase 3
1,160
Gyeonggi-do, Seoul, Songpa-gu
2024-11-27
Recruiting
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)
AstraZeneca
Phase 2
270
Seoul
2024-11-27
Recruiting
YOUNGIL KOH
Phase 1/2
75
Hwasun, Seoul
2024-11-26
Active, closed
Samsung Medical Center
Phase 2
30
Seoul
2024-11-26
Recruiting
NOBO Medicine
Phase 2
33
Busan, Hwasun, Ilsan, Seongnam, Seoul, Ulsan
2024-11-25
Active, closed
Genmab
Phase 3
191
Suwon, Cheongju-si, Daegu, Goyang-si, Seoul
2024-11-25
Recruiting
Phase 1 Single Ascending Dose Study
NCT06934941Healthy Subjects
Neuramedy Co. Ltd.
Phase 1
36
Seoul
2024-11-25
Recruiting
Validation Study of CART BP as a Wearable Cuffless Blood Pressure Monitor
NCT06513975Blood Pressure, Hypertension, Blood Pressure, High, Blood Pressure, Low
Sky Labs
Not applicable
50
Seoul
2024-11-22
Recruiting
Washington University School of Medicine
Phase 2/3
280
Seoul
2024-11-22
Recruiting
Shanghai Henlius Biotech
Phase 3
550
Cheongju-si, Jinju, Seoul
2024-11-22
Recruiting
Washington University School of Medicine
Phase 2/3
280
Seoul
2024-11-22
Recruiting
Kyu Chang Won
Not applicable
5,950
Daegu, Seoul
2024-11-21
Active, closed
GC Biopharma Corp
Phase 1
9
Suwon, Seoul
2024-11-21
Active, closed
Merck Sharp & Dohme LLC
Phase 3
67
Pusan Kwangyokshi, Daejeon, Seoul
2024-11-21
Recruiting
UCB Biopharma SRL
Phase 3
450
Busan, Incheon, Seoul, Suwon
2024-11-21
Recruiting
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
NCT06690775Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer
TORL Biotherapeutics, LLC
Phase 2
230
Seoul
2024-11-20
Recruiting
GIST Oral Paclitaxel(Liporaxel)
NCT06326346Gastrointestinal Stromal Tumors
Asan Medical Center
Phase 2
28
Seoul
2024-11-20
Active, closed
Daiichi Sankyo
Phase 3
700
Busan, Daegu, Hwasun-gun, Incheon, Jeonju, Seongnam-si, Seoul, Suwon
2024-11-19
Recruiting
Seoul St. Mary's Hospital
Not applicable
800
Incheon, Seoul, Suwon, Uijeongbu-si
2024-11-19
By invitation
UCB Biopharma SRL
Phase 3
8
Seoul
2024-11-19
Recruiting
Eli Lilly and Company
Phase 3
125
Seongnam-si, Seoul
2024-11-18
Recruiting
Yonsei University
Observational
500
Seoul
2024-11-18
Recruiting
AstraZeneca
Phase 3
1,160
Changwon-si, Cheongju-si, Incheon, JinJoo, Seoul, Suwon
2024-11-18
Active, closed
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
Endeavor Biomedicines, Inc.
Phase 2
213
Seoul, Ulsan, Busan
2024-11-15
Recruiting
Daiichi Sankyo
Phase 1
150
Seoul
2024-11-14
Recruiting
Takeda
Observational
168
Seoul
2024-11-14
Not yet open
Individualized Automatic Coaching Message for Glycemic Management and Depressive Symptom
NCT06684678Diabetes Mellitus, Type 1, Continuous Glucose Measurement
Samsung Medical Center
Not applicable
140
Seoul
2024-11-13
Recruiting
Samsung Medical Center
Not applicable
72
Seoul
2024-11-13
Recruiting
IlDong Pharmaceutical Co Ltd
Phase 1
36
Seoul
2024-11-13
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Bucheon-si, Busan, Incheon, Seoul, Wŏnju
2024-11-12
Active, closed
GlaxoSmithKline
Phase 2
283
Ansan, Busan, Pusan, Seoul
2024-11-11
Active, closed
Amgen
Phase 2
409
Seongnam-si, Gyeonggi-do, Seoul
2024-11-07
Recruiting
Deep Neuromuscular Blockade on Postoperative Pain
NCT06679569Neuromuscular Blockade
Seoul National University Hospital
Not applicable
106
Seoul
2024-11-06
Recruiting
Yonsei University
Observational
300
Seoul
2024-11-05
Recruiting
PULSED AF Post-Approval Study
NCT06578104Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
580
Daegu, Seoul
2024-11-04
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
180
Seodaemun-gu, Seoul
2024-11-03
Recruiting
Jeil Pharmaceutical Co., Ltd.
Observational
3,000
Seoul
2024-11-02
Not yet open
Seoul National University Hospital
Phase 4
160
Seoul
2024-11-01
By invitation
Samsung Medical Center
Observational
51
Seoul
2024-11-01
Active, closed
Seoul National University
Observational
2,000
Seoul
2024-11-01
Active, closed
A Study of ZW191 in Participants With Solid Tumors
NCT06555744Advanced Solid Tumors
Zymeworks BC Inc.
Phase 1
145
Goyang-si, Seongnam-si, Seoul
2024-10-30
Active, closed
A Study of Mosliciguat in PH-ILD
NCT06635850Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases
Pulmovant, Inc.
Phase 2
135
Incheon, Dongjak, Seoul
2024-10-29
Recruiting
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
NCT06625775Solid Tumor, Adult, Metastatic Breast Cancer, Advanced Breast Cancer, HER2 Mutation-Related Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
392
Seoul
2024-10-29
Recruiting
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
NCT06663332Crohns Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Arthritis, Juvenile
Janssen Research & Development, LLC
Phase 3
196
Seoul
2024-10-29
Active, closed
Novartis Pharmaceuticals
Phase 2
96
Seoul
2024-10-29
Recruiting
SUK MIN SEO
Not applicable
200
Seoul
2024-10-24
Recruiting
Study of DM5167 in Patients With Advanced Solid Tumors
NCT07101601Advanced Breast Cancer
DIGMBIO
Phase 1
58
Gyeonggi-do, Seoul
2024-10-24
Recruiting
Yonsei University
Observational
350
Seoul
2024-10-24
Active, closed
Jetema Co., Ltd.
Not applicable
149
Seoul
2024-10-22
Recruiting
Pierre Fabre Medicament
Phase 1/2
140
Seoul
2024-10-22
Recruiting
Samsung Medical Center
Observational
100,000
Seoul
2024-10-22
Recruiting
Onconic Therapeutics Inc.
Phase 3
364
Seoul
2024-10-22
Recruiting
BnH Research
Phase 1
92
Seoul
2024-10-22
Active, closed
Anterogen Co., Ltd.
Phase 1
6
Seoul
2024-10-22
Recruiting
Pfizer
Phase 3
900
Hwasun, Goyang-si, Seoul, Daegu, Junggu
2024-10-22
Recruiting
Merck Sharp & Dohme LLC
Phase 3
680
Goyang-si, Suwon, Seoul
2024-10-21
Active, closed
Pfizer
Phase 3
609
Hwasun, Goyang-si, Seoul, Daegu
2024-10-21
Recruiting
Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease Treatment
NCT06618638ADPKD (autosomal Dominant Polycystic Kidney Disease)
Seoul National University Hospital
Not applicable
340
Anyang-si, Seoul, Busan, Daegu, Gwangju
2024-10-21
Recruiting
Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
NCT06257394Acute Lymphoblastic Leukemia, Pediatric
Hyoung Jin Kang
Phase 2
74
Daegu, Daejeon, Hwasun, Jeju City, Seoul, Yangsan
2024-10-20
Recruiting
BeOne Medicines
Phase 1
153
PaldalGu SuwonSi, Seongnam-si, GangnamGu, SeochoGu, SeodaemunGu, Seoul, SongpaGu
2024-10-18
Active, closed
Novartis Pharmaceuticals
Phase 2
251
Yangsan, Seoul
2024-10-17
Recruiting
UCB Biopharma SRL
Phase 2/3
8
Seoul
2024-10-16
Recruiting
Yonsei University
Phase 4
200
Seoul
2024-10-15
Recruiting
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
NCT06663319Colorectal Neoplasms, Gastrointestinal Neoplasms
Janssen Research & Development, LLC
Phase 1
260
Seoul
2024-10-15
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Bucheon-si, Busan, Deagu, Incheon, Seoul, Wŏnju
2024-10-14
Active, closed
Merck Sharp & Dohme LLC
Phase 2
66
Seoul
2024-10-14
Active, closed
Ipsen
Observational
424
Busan, Seongnam-si, Seoul
2024-10-14
Active, closed
Pfizer
Observational
660
Seoul
2024-10-11
Recruiting
Boehringer Ingelheim
Phase 2
588
Seoul
2024-10-11
Active, closed
Ipsen
Phase 2
670
Gyeonggi-do, Seoul
2024-10-10
Active, closed
Incyte Corporation
Phase 3
349
Ansan-si, Bucheon-si, Busan, Incheon, Jeonju, Seoul
2024-10-10
Active, closed
Novartis Pharmaceuticals
Phase 2
203
Seoul
2024-10-09
Recruiting
Seoul National University Hospital
Phase 4
84
Seoul
2024-10-09
Active, closed
SynOx Therapeutics Limited
Phase 3
128
Seoul
2024-10-09
Recruiting
Rznomics, Inc.
Phase 1/2
43
Incheon, Seongnam-si, Seoul
2024-10-08
Recruiting
Bristol-Myers Squibb
Phase 3
1,000
Cheongju-si, Namdong-gu, Hwasun, Goyang-si, Seongnam-si, Yangsan, Busan, Seoul
2024-10-07
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Akero Therapeutics, Inc
Phase 3
2,150
Nam-Gu, Daegu, Wŏnju, Incheon, Goyang-si, Seoul
2024-10-04
Recruiting
Eunpyeong St. Mary's Hospital
Observational
500
Seoul
2024-10-02
Recruiting
Yuhan Corporation
Phase 1/2
201
Seongnam-si, Suwon, Cheongju-si, Seoul
2024-10-02
Active, closed
Taiho Oncology, Inc.
Phase 2/3
15
Seoul
2024-10-01
Recruiting
Ferring Pharmaceuticals
Phase 3
454
Goyang-si, Yangsan, Hwasun, Seoul
2024-10-01
Recruiting
Reduced Vaccine Response to HZ/su in SLE
NCT07636044Vaccine Reaction, Zoster, Systemic Lupus Erythematosus
Seoul National University Hospital
Observational
80
Seoul
2024-10-01
Recruiting
Yonsei University
Phase 3
176
Seoul
2024-10-01
Recruiting
GlaxoSmithKline
Phase 1
845
Gyeonggi-do, Seoul
2024-09-30
Recruiting
Jeeyun Lee
Phase 1/2
61
Seoul
2024-09-30
By invitation
Sanofi
Phase 2
900
Seoul
2024-09-30
Active, closed
Kangbuk Samsung Hospital
Not applicable
120
Seoul
2024-09-30
Recruiting
GlaxoSmithKline
Phase 2
350
Ansan, Bucheon-si, Daegu, Seoul, Suwon Gyeonggi-do
2024-09-27
Active, closed
Stemline Therapeutics, Inc.
Phase 3
4,556
Cheongju-si, Seongnam-si, Incheon, Seoul, Busan, Daegu, Gyeonggi-do, Ulsan
2024-09-27
Recruiting
Nostril Side on Epistaxis
NCT06605989Nasotracheal Intubation
Seoul National University Hospital
Not applicable
208
Seoul
2024-09-26
Active, closed
Boehringer Ingelheim
Phase 3
1,666
Bucheon-si, Seongnam, Seoul
2024-09-26
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Ansan-si, Yongin-si, Seoul, Yeongdeungpo-gu, Gangwon-do
2024-09-26
Active, closed
Genmab
Phase 3
699
Busan, Goyang-si, Hwasun, Seoul, Suwon
2024-09-25
Active, closed
Hoffmann-La Roche
Phase 3
338
Gyeonggi-do, Incheon, Jeollanam-do, Seongnam-si, Seoul
2024-09-23
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
160
Seoul
2024-09-20
Recruiting
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
NiKang Therapeutics, Inc.
Phase 1
238
Gwangmyeong, Seoul
2024-09-19
Active, closed
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
Eli Lilly and Company
Phase 1
340
Ilsandong-gu, Seoul, Suwon
2024-09-19
Active, closed
argenx
Phase 3
141
Daegu, Seoul
2024-09-18
Active, closed
NS-050/NCNP-03 in Boys With DMD (Meteor50)
NCT06053814Duchenne Muscular Dystrophy
NS Pharma, Inc.
Phase 1/2
20
Yangsan, Seoul
2024-09-18
Active, closed
Dianthus Therapeutics
Phase 2
46
Daegu, Seoul
2024-09-17
Active, closed
Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)
NCT06430866Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Amgen
Phase 3
163
Suwon, Jeonju, Cheongju-si, Busan, Incheon, Seoul
2024-09-12
Recruiting
Yonsei University
Phase 2
92
Seongnam-si, Goyang-si, Seoul
2024-09-12
Recruiting
GlaxoSmithKline
Phase 3
440
Bucheon Kyunggi-Do, Seoul, Suwon Kyunggi-do, Yongsan-Ku Seoul
2024-09-11
Recruiting
Bristol-Myers Squibb
Observational
15
Hwasun, Seoul
2024-09-11
Active, closed
Yonsei University
Not applicable
196
Seoul
2024-09-11
Active, closed
Amgen
Phase 3
315
Suwon, Jeonju, Cheongju-si, Seoul
2024-09-09
Recruiting
Daewon Pharmaceutical Co., Ltd.
Phase 3
274
Seoul
2024-09-09
Active, closed
CellinCells
Observational
3
Seoul
2024-09-06
Active, closed
Takeda
Phase 3
2,099
Wŏnju, Gwangju, Beon-gil Bundang-gu, Bucheon-si, Gwangjin-Gu, Seocho-Gu, Seoul
2024-09-04
Recruiting
AbbVie
Phase 2
590
Busan, Daejeon, Seoul, Daegu
2024-09-04
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Seoul
2024-09-04
Recruiting
Gossamer Bio USA, Inc.
Phase 3
330
Seoul
2024-09-03
Active, closed
Evaluation of 'WAYMED Endo CL CS' for Automated Detection and Diagnosis of Colorectal Adenoma and Non-Adenoma Lesions
NCT07470827Colorectal Adenoma, Sessile Serrated Lesion, Hyperplastic Polyp, Carcinoma
WAYCEN Inc
Observational
1,178
Seoul
2024-09-01
Recruiting
NEXTGEN Bioscience
Phase 2
73
Seoul
2024-09-01
Not yet open
Yonsei University
Not applicable
10
Seoul
2024-09
Not yet open
Yonsei University
Observational
10,000
Seoul
2024-09
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Anyang, Cheonan, Daegu, Daejeon, Gangwon-do, Goyang-si, Seongnam-si, Seoul
2024-08-30
Recruiting
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
NCT06351592Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Regeneron Pharmaceuticals
Phase 1/2
54
Seoul
2024-08-28
Recruiting
Seoul National University Hospital
Not applicable
200
Seoul
2024-08-27
Active, closed
Ferring Pharmaceuticals
Observational
1,526
Busan, Daegu, Seongnam-si, Seoul
2024-08-27
Active, closed
AstraZeneca
Phase 2
194
Seongnam, Seoul, Suwon
2024-08-27
Recruiting
Janssen Research & Development, LLC
Phase 2
210
Seoul
2024-08-26
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
Seoul
2024-08-22
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
AstraZeneca
Phase 2
257
Incheon, Namdong-gu, Seoul
2024-08-22
Recruiting
Bristol-Myers Squibb
Observational
505
Seoul
2024-08-21
Recruiting
Yonsei University
Observational
1,200
Seoul
2024-08-21
Recruiting
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
NCT06395103B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
Merck Sharp & Dohme LLC
Phase 1/2
90
Seoul
2024-08-16
Recruiting
Samsung Medical Center
Phase 2
30
Seoul
2024-08-13
Recruiting
Seoul National University
Not applicable
360
Seoul
2024-08-12
Recruiting
AstraZeneca
Phase 3
620
Busan, Gyeonggi-do, Hwasun-gun, Seongnam-si, Seoul
2024-08-12
Recruiting
Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
NCT06184009Pediatric Acute Lymphoblastic Leukemia
Jae Wook Lee
Phase 2
370
Seoul, Incheon, Suwon, Yangsan
2024-08-10
Active, closed
EMD Serono Research & Development Institute, Inc.
Phase 1
60
Seongnam, Seoul
2024-08-07
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
Merck Sharp & Dohme LLC
Phase 1/2
210
Seoul
2024-08-07
Recruiting
AstraZeneca
Phase 3
1,018
Busan, Goyang-si, Jeonnam, Seoul
2024-08-07
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
220
Seoul
2024-08-07
Recruiting
Anesthesia and Non-small Cell Lung Cancer Recurrence
NCT06330038Non-small Cell Lung Cancer, Surgery, Anesthesia
Samsung Medical Center
Phase 4
5,384
Seoul
2024-08-05
Recruiting
CHA University
Phase 4
490
Seongnam-si, Daegu, Iksan, Ilsan, Seongnam, Seoul, Wŏnju
2024-08-05
Active, closed
BioNTech SE
Phase 2
110
Cheongju-si, Daegu, Goyang-si, Incheon, Jinju, Seoul, Suwon
2024-08-05
Recruiting
Yonsei University
Not applicable
10
Seoul
2024-08-01
By invitation
Federal University of São Paulo
Observational
4,500
Seoul
2024-08-01
Active, closed
GlaxoSmithKline
Phase 3
10,212
Seoul, Ansan, Bucheon-si Kyunggi-do 14584, Daegu, Incheon, Jeonju, Kangwon-do, Suwon Gyeonggi-do
2024-08-01
Recruiting
Addpharma Inc.
Phase 3
251
Seoul
2024-07-31
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Daegu, Gwangju, Seoul
2024-07-31
By invitation
Viatris Innovation GmbH
Phase 3
680
Seoul
2024-07-30
Recruiting
Exercise Program in Patients With Nontuberculous Mycobacterial Pulmonary Disease
NCT06488495Nontuberculous Mycobacterial Pulmonary Disease
Yonsei University
Not applicable
50
Seoul
2024-07-24
Recruiting
Bristol-Myers Squibb
Observational
600
Seoul
2024-07-24
Active, closed
Il-Yang Pharm. Co., Ltd.
Phase 3
416
Seoul
2024-07-23
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
NCT06427941Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
BeOne Medicines
Phase 1/2
630
Cheongju-si, BundangGu SeongnamSi, Seongnam-si, GangnamGu, SeodaemunGu, Seoul, SongpaGu
2024-07-23
Recruiting
PulseSelect™ PFA Global Registry
NCT06393920Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
1,950
Seongnam-si, Seoul
2024-07-23
Recruiting
Jazz Pharmaceuticals
Phase 3
286
Bundang-Gu, Seongnam-Si, Ilsandong-gu, Goyang-si, Seongnam-si, Busan, Seoul
2024-07-19
Active, closed
TME Alteration in HER2 Positive Breast Cancer
NCT06533670Breast Cancer, HER2-positive Breast Cancer, Chemotherapy Effect
Seoul National University Hospital
Observational
30
Seoul
2024-07-19
Recruiting
Samsung Medical Center
Phase 3
248
Seoul
2024-07-19
Recruiting
GlaxoSmithKline
Phase 3
150
Jeonju, Seoul
2024-07-19
Recruiting
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT06590857Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
DrugRYZ101
RayzeBio, Inc.
Phase 1/2
64
Seoul
2024-07-19
Recruiting
Seoul National University Hospital
Observational
30
Seoul
2024-07-18
Recruiting
AstraZeneca
Phase 2
80
Busan, Daegu, Gyeongsangnam-do, Incheon, Jeonju, Seogu, Seoul, Suwon
2024-07-16
Active, closed
Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years
NCT06409494Varicella Zoster Virus Infection, Herpes Zoster
EuBiologics Co.,Ltd
Phase 1
72
Seoul
2024-07-15
Recruiting
Woo-Keun Seo
Not applicable
1,556
Seoul
2024-07-15
Recruiting
Boryung Pharmaceutical Co., Ltd
Observational
1,052
Seoul, Uijeongbu-si
2024-07-15
Active, closed
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Sanofi
Phase 3
109
Seoul
2024-07-12
Recruiting
Arbutus Biopharma Corporation
Observational
50
Seoul
2024-07-11
By invitation
Yonsei University
Phase 2
27
Seoul
2024-07-11
Active, closed
Celldex Therapeutics
Phase 3
963
Seongdong, Ansan, Seongnam-si, Seoul, Suwon
2024-07-11
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Servier Bio-Innovation LLC
Phase 3
156
Seoul
2024-07-09
Recruiting
Sanofi
Phase 1
96
Busan, Goyang-si, Seoul
2024-07-08
Active, closed
Jaseng Medical Foundation
Not applicable
250
Bucheon-si, Daejeon, Haeundae, Seoul, Yangsan
2024-07-07
Recruiting
Study of WAL0921 in Patients With Glomerular Kidney Diseases
NCT06466135Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
Walden Biosciences
Phase 2
96
Anyang, Busan, Seongnam-si, Seoul, Soeul, Suwon
2024-07-02
Recruiting
Korea University Anam Hospital
Not applicable
15
Seoul
2024-07-01
Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT06465069Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
Eli Lilly and Company
Phase 1
460
Seoul
2024-07-01
Recruiting
Myeloid Therapeutics
Phase 1
70
Busan, Gyeonggi-do, Seoul
2024-07-01
Not yet open
Seoul St. Mary's Hospital
Not applicable
152
Seoul
2024-07
Active, closed
AstraZeneca
Phase 3
339
Seoul
2024-06-29
Recruiting
Boehringer Ingelheim
Phase 1/2
910
Seongnam-si, Seoul
2024-06-28
Active, closed
AbbVie
Phase 3
1,400
Busan, Cheonan-si, Ansan-si, Seongnam, Seoul
2024-06-27
Recruiting
Immunotherapy in Lymphoma
NCT06796517Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma Relapsed, Primary Mediastinal Large B-Cell Lymphoma
Sung-Soo Park
Observational
72
Seoul
2024-06-26
Recruiting
Gangnam Severance Hospital
Phase 3
440
Seoul
2024-06-26
Active, closed
Genmab
Phase 3
621
Busan, Goyang-si, Hwasun, Seoul, Soeul, Suwon
2024-06-25
Recruiting
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Daegu, Gwangju, Seoul
2024-06-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,530
Seoul
2024-06-24
Recruiting
Prevention of Acute Cholecystitis With ETGBD
NCT06287112Biliary Obstruction, Acute Cholecystitis
Seoul National University Hospital
Not applicable
35
Seoul
2024-06-20
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
220
Seoul
2024-06-20
Recruiting
Allogene Therapeutics
Phase 2
250
Seogu, Goyang-si, Suwon, Hwasun, Seoul
2024-06-18
Recruiting
Real-World Treatment Study of Koselugo (Selumetinib)
NCT06360406Neurofibromatosis 1, Neurofibroma, Plexiform
AstraZeneca
Observational
200
Busan, Chungcheongbuk-do, Daejeon, Gyeonggi-do, Incheon, Jeonnam, Seoul, Wŏnju
2024-06-15
Active, closed
Extended Validation of Donor-derived Cell-free DNA in Kidney Transplant Recipients
NCT07805343Rejection Acute Renal, Rejection Chronic Renal, Transplantation, Kidney Rejection Transplant
Paris Translational Research Center for Organ Transplantation
Observational
5,000
Seoul
2024-06-15
Active, closed
AbbVie
Phase 3
184
Ansan-si, Bucheon-si, Suwon, Seoul
2024-06-14
Recruiting
Evaluation of Safety of Acellular Dermal Matrix(ADM) in Breast Reconstruction
NCT06555614Breast Cancer Female, Breast Reconstruction
DOF Inc.
Observational
120
Seoul
2024-06-13
Recruiting
Efficacy and Safety of SPC1001 in Patients With Essential Hypertension
NCT06826872Hypertension, Essential, Cardiovascular Diseases, Cardiology
Shin Poong Pharmaceutical Co. Ltd.
Phase 2
252
Seoul
2024-06-12
Active, closed
Daewoong Pharmaceutical Co. LTD.
Observational
471
Seoul
2024-06-11
Active, closed
Daewoong Pharmaceutical Co. LTD.
Observational
200
Seoul
2024-06-11
Recruiting
Sehhoon Park
Phase 2
47
Seoul
2024-06-11
Recruiting
Merck Sharp & Dohme LLC
Phase 3
851
Bupyeong-gu, Yangsan, Busan, Deagu, Daejeon, Seoul
2024-06-10
Active, closed
Janssen Research & Development, LLC
Phase 1
108
Seoul
2024-06-07
Active, closed
Exelixis
Phase 2/3
600
Busan, Suwon, Yangsan, Jeonju, Seoul
2024-06-07
Recruiting
Cohort Study for Gastric MALT Lymphoma
NCT06454149Gastric MALT Lymphoma
Seoul National University Hospital
Observational
300
Ansan-si, Seongnam-si, Seoul
2024-06-06
Active, closed
Amgen
Phase 3
563
Cheongju Chungbuk, Goyang-si Gyeonggi-do, Seongnam-si, Gyeonggi-do, Seoul
2024-06-05
Recruiting
Kartos Therapeutics, Inc.
Phase 3
600
Busan, Daegu, Seoul
2024-06-03
Recruiting
Sang-Won Um
Not applicable
200
Seoul
2024-06-01
Recruiting
Yonsei University
Not applicable
314
Seoul
2024-06
Active, closed
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT06328738HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification
Enliven Therapeutics
Phase 1
275
Seongnam-si, Seoul, Soeul, Suwon
2024-05-30
Recruiting
Dong Wha Pharmaceutical Co. Ltd.
Phase 4
196
Seoul
2024-05-28
Active, closed
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT06470438Lymphoma, Non-Hodgkin, Refractory B-Cell NHL, Relapsed B-cell NHL
Janssen Research & Development, LLC
Phase 1
58
Seoul
2024-05-28
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Hoffmann-La Roche
Phase 3
1,800
Bucheon-si, Busan, Daegu, Incheon, Seoul
2024-05-24
Recruiting
HK inno.N Corporation
Observational
6,713
Seoul
2024-05-22
Recruiting
A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
NCT06220773Essential Hypertension, Type 2 Diabetes Mellitus
Boryung Pharmaceutical Co., Ltd
Phase 3
276
Seoul
2024-05-21
Recruiting
Daiichi Sankyo
Phase 3
540
Cheongju-si, Daegu, Seongnam-si, Seoul, Suwon
2024-05-21
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Gwangju, Seoul
2024-05-21
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Wŏnju, Seoul
2024-05-20
Recruiting
Seoul National University Hospital
Observational
90
Seoul
2024-05-20
Active, closed
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
54
Seongnam-si, Busan, Goyang-si, Seoul, Cheongju-si, Incheon, Suwon
2024-05-20
Active, closed
The OPBC-07/microNAC Study
NCT06529302Breast Cancer
University Hospital, Basel, Switzerland
Observational
2,000
Seoul
2024-05-15
Recruiting
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
NCT06295731Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
Inhibrx Biosciences, Inc
Phase 2/3
450
Seoul, Yangsan, Daegu
2024-05-14
Recruiting
Yonsei University
Not applicable
642
Seoul
2024-05-13
Active, closed
Phase I, First-In Human Study to Evaluate Safety and Tolerability of EuRSV in Healthy Adults Aged Between 19 Years and 80 Years
NCT06216093Respiratory Syncytial Virus Infections, Respiratory Syncytial Virus (RSV)
EuBiologics Co.,Ltd
Phase 1
100
Seoul
2024-05-08
Active, closed
Sanofi
Phase 3
1,541
Daegu, Gwangju, Ansan-si, Seongnam-si, Suwon, Yangsan, Bupyeong-gu, Seoul
2024-05-08
Recruiting
SMG-SNU Boramae Medical Center
Not applicable
40
Seoul
2024-05-07
Active, closed
Merck Sharp & Dohme LLC
Phase 3
473
Seongnam, Seoul
2024-05-03
Recruiting
Yonsei University
Observational
250
Seoul
2024-05-01
Recruiting
Samsung Medical Center
Phase 1/2
37
Seoul
2024-05-01
Not yet open
Samsung Medical Center
Phase 2
40
Seoul
2024-05-01
Recruiting
Thoracoscopic Versus Catheter Ablation in Persistent Atrial Fibrillation With Enlarged Left Atrium
NCT07783984Atrial Fibrillation, Thoracoscopic Ablation, Endocardial Ablation
Samsung Medical Center
Not applicable
194
Seoul
2024-05-01
Recruiting
Seoul National University Hospital
Not applicable
128
Seoul
2024-04-30
Recruiting
AstraZeneca
Phase 3
582
Goyang-si, Namdong-gu, Seoul, Suwon
2024-04-29
Recruiting
Eli Lilly and Company
Phase 3
510
Busan, Gyeonggi-do, Pusan, Seongnam-si, Seoul, Suwon
2024-04-29
Active, closed
Left Bundle Branch Area Pacing Versus Right Ventricular Pacing in Atrioventricular Block With Preserved Ejection Fraction
NCT07464041Atrioventricular Block, Left Bunde Branch Area Pacing, Conduction System Pacing
Samsung Medical Center
Not applicable
200
Wŏnju, Seoul, Changwon
2024-04-29
Recruiting
CSL Behring
Phase 2/3
3,110
Ilsan-gu, Anyang-si, Daegu, Gangnam-gu, Goyang-si, Guri-si, Gwangju, Seoul
2024-04-27
Active, closed
Eli Lilly and Company
Phase 3
450
Busan, Incheon, Seongnam-si, Seoul
2024-04-26
Recruiting
Seung-Jung Park
Not applicable
960
Seoul, Ansan, Anyang, Bucheon-si, Busan, Changwon, Chuncheon, Daegu
2024-04-25
By invitation
ACADIA Pharmaceuticals Inc.
Phase 3
752
Seoul, Incheon
2024-04-23
Recruiting
Karyopharm Therapeutics Inc
Phase 2
58
Seocho, Seoul, Busan
2024-04-22
Recruiting
Janssen Research & Development, LLC
Phase 1/2
287
Seoul
2024-04-22
Recruiting
Quantitative Analysis of EEG Changes in Response to Nociception
NCT06342570Patients Undergoing Laparoscopic Surgery
Gangnam Severance Hospital
Observational
109
Seoul
2024-04-21
Active, closed
AstraZeneca
Phase 2
76
Cheongju-si, Seongnam-si, Seoul, Suwon
2024-04-21
Recruiting
Bristol-Myers Squibb
Observational
3,000
Seoul
2024-04-19
Recruiting
Janssen Research & Development, LLC
Phase 3
641
Chuncheon, Gyeongin, Sangam-dong, Seoul
2024-04-18
Active, closed
GlaxoSmithKline
Phase 4
1,358
Busan, Daegu, Seongnam-si Gyeonggi-do, Seoul, Suwon Kyunggi-do
2024-04-16
Recruiting
Samsung Medical Center
Phase 3
88
Seoul
2024-04-16
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
Sanofi
Phase 3
2,500
Goyang-si, Seoul
2024-04-16
Recruiting
A Phase 2b/3 Study of TPX-115 on Partial-thickness Rotator Cuff Tear
NCT06414005Partial Thickness Rotator Cuff Tear
Tego Science, Inc.
Phase 2/3
166
Seongnam-si, Seoul
2024-04-15
By invitation
Hangang Sacred Heart Hospital
Not applicable
5
Seoul
2024-04-15
Recruiting
Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
NCT05754710Psoriatic Arthritis, Juvenile, Polyarticular Juvenile Idiopathic Arthritis
Pfizer
Observational
10
Seoul
2024-04-12
Recruiting
Seoul National University
Observational
730
Seoul
2024-04-11
Recruiting
Korea University Anam Hospital
Phase 1/2
10
Seoul
2024-04-11
Active, closed
Merck Sharp & Dohme LLC
Phase 2
272
Seoul
2024-04-10
Active, closed
Janssen Research & Development, LLC
Phase 3
272
Chungcheongbuk Do, Daegu, Gyeonggi-do, Jeollanam-do, Seoul, Yangsan
2024-04-09
Active, closed
Amgen
Phase 3
434
Gwangju, Seoul
2024-04-08
Recruiting
Ho Joon Im
Phase 2
90
Daegu, Daejeon, Hwasun, Jeju City, Seoul, Yangsan
2024-04-04
Active, closed
Amgen
Phase 4
32
Goyang-si, Seoul
2024-04-02
Active, closed
L&C Bio
Not applicable
80
Seongnam-si, Seoul
2024-04-01
Active, closed
AstraZeneca
Phase 3
2,554
Ansan-si, Anyang-si, Busan, Cheonan-si, Daejeon, Goyang-si, Gwangju, Seoul
2024-03-29
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
Alexion Pharmaceuticals, Inc.
Phase 3
584
Anyang-si, Busan, Deagu, Gwangju, Gyeonggi-do, Seoul, Suwon
2024-03-29
Active, closed
Gilead Sciences
Phase 2
228
Busan, Daegu, Daejeon, Guri-si, Jongno-Gu, Nam-Gu, Seongdong-gu, Seoul
2024-03-27
Recruiting
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
NCT07699328EGFR-Mutant Non-Small Cell Lung Cancer
Voronoi, Inc
Phase 1/2
315
Seongnam-si, Suwon, Cheongju-si, Seoul
2024-03-26
Recruiting
Bristol-Myers Squibb
Observational
104
Seoul
2024-03-25
Recruiting
OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts
NCT06227754ST Elevation Myocardial Infarction, Myocardial Infarction
Chonnam National University Hospital
Not applicable
1,500
Daegu, Gwangju, Iksan, Incheon, Jeju City, Jeonju, Jinju, Seoul
2024-03-25
Recruiting
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
Iambic Therapeutics, Inc
Phase 1
383
Seoul
2024-03-25
Recruiting
GlaxoSmithKline
Phase 3
864
Busan, Pusan, Seoul, Suwon Gyeonggi-do
2024-03-21
Recruiting
Samsung Medical Center
Not applicable
50
Seoul
2024-03-18
Recruiting
Verastem, Inc.
Phase 3
270
Seongnam, Seoul
2024-03-18
Recruiting
A Pan-Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
NCT06418412Advanced EGFR Exon 20 Insertion Mutated Non-Small Cell Lung Cancer
National Cancer Centre, Singapore
Observational
600
Seoul
2024-03-15
Recruiting
Boryung Pharmaceutical Co., Ltd
Observational
8,606
Seoul
2024-03-15
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Hoffmann-La Roche
Phase 3
1,350
Busan, Daegu, Gyeonggi-do, Incheon, Seoul
2024-03-13
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Busan, Daegu, Seoul
2024-03-13
Active, closed
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,942
Busan, Daegu, Donggu, Goyang, Seoul, Uijeongbu-si, Ulsan
2024-03-13
Recruiting
Eli Lilly and Company
Phase 3
90
Busan, Daegu, Seoul
2024-03-13
Active, closed
Janssen Research & Development, LLC
Phase 3
731
Ansan-si, Anyang-si, Bucheon-si, Gwangju, Seongnam, Seoul
2024-03-09
By invitation
Active Surveillance for Low-risk Papillary Thyroid Carcinoma
NCT06261190Thyroid Cancer, Papillary Thyroid Carcinoma
National Cancer Center, Korea
Observational
499
Goyang-si, Seongnam, Seoul
2024-03-06
Recruiting
Yonsei University
Not applicable
140
Seoul
2024-03-06
Active, closed
Eli Lilly and Company
Phase 3
17,300
Bucheon-si, Daegu, Daejeon, Dongjak-gu, Gwangju, Namdong-gu, Seongnam, Seoul
2024-03-05
Recruiting
Hee Young Ju
Phase 2
116
Seoul, Yangsan, Daegu, Daejeon, Hwasun, Jeju City, Seongnam, Suwon
2024-03-05
Recruiting
Yonsei University
Not applicable
304
Seoul
2024-03-04
Recruiting
Seoul National University Hospital
Observational
260
Seoul
2024-03-01
Recruiting
Yonsei University
Phase 2
116
Seoul
2024-03-01
Recruiting
To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM
NCT06293417T2DM (Type 2 Diabetes Mellitus), Dyslipidemias
Korea University Anam Hospital
Not applicable
3,958
Seoul
2024-03-01
Active, closed
Novartis Pharmaceuticals
Phase 3
1,466
Bundang Gu, Gyeonggi-do, Seoul, Incheon, Seongnam Gyeonggi
2024-02-28
Recruiting
Effect of Ezetimibe on Gut Microbiota
NCT06784557Atherosclerotic Cardiovascular Disease With Dyslipidemia
Yonsei University
Phase 4
110
Seoul
2024-02-28
Recruiting
Daiichi Sankyo
Phase 2/3
860
Goyang-si, Seongnam, Seongnam-si, Seoul
2024-02-27
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
Daiichi Sankyo
Phase 2
740
Daegu, Gyeonggi-do, Seongnam, Seoul
2024-02-26
Rows per page Showing 1001–1500 of 2866
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a South Korean investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 November 2026. https://priyalifescience.com/clinical-trials-south-korea/city/seoul?page=3

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in South Korea and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,409 studies in total at the last sync on 17 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,866 of those studies with a site in Seoul.

How many clinical trials are recruiting in Seoul?

1,560 of the 2,866 studies on this page are recruiting new participants as of the 17 Nov 2026, 03:18 UTC sync. A further 209 have not yet opened recruitment, 1,016 are active but closed to new participants, and 81 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.